What REGENERON PHARMACEUTICALS, INC.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 60 | 134 |
| Total trades | 82 | 200 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 90,998 | 516,614 |
| Disposed | 95,749 | 482,636 |
| Net activity | −4,751 | +33,978 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Pitofsky Jason | SVP Controller | Nov 04 | Open-market sale · S Common Stock | −179 | $950.76 | −$170K | 0 |
| Pitofsky Jason | SVP Controller | Nov 04 | Open-market sale · S Common Stock | −35 | $945.61 | −$33.1K | 4,272 |
| Pitofsky Jason | SVP Controller | Nov 04 | Open-market sale · S Common Stock | −108 | $944.22 | −$102K | 4,307 |
| Pitofsky Jason | SVP Controller | Nov 04 | Open-market sale · S Common Stock | −529 | $943.53 | −$499K | 4,415 |
| Pitofsky Jason | SVP Controller | Nov 04 | Open-market sale · S Common Stock | −1,215 | $942.31 | −$1.14M | 4,944 |
| Pitofsky Jason | SVP Controller | Nov 04 | Open-market sale · S Common Stock | −982 | $941.58 | −$925K | 6,159 |
| Pitofsky Jason | SVP Controller | Nov 04 | Open-market sale · S Common Stock | −575 | $940.46 | −$541K | 7,141 |
| Pitofsky Jason | SVP Controller | Nov 04 | Open-market sale · S Common Stock | −439 | $939.57 | −$412K | 7,716 |
| Pitofsky Jason | SVP Controller | Nov 04 | Exercise / conversion · M Common Stock | +905 | $492.00 | +$445K | 8,155 |
| Pitofsky Jason | SVP Controller | Nov 04 | Exercise / conversion · M Common Stock | +1,478 | $644.54 | +$953K | 7,250 |
| Pitofsky Jason | SVP Controller | Nov 04 | Exercise / conversion · M Common Stock | +1,500 | $726.53 | +$1.09M | 5,772 |
| Murphy Andrew J | Co-Chief Scientific Officer | Nov 03 | Gift · G Common Stock | −1,054 | — | — | 46,779 |
| Zoghbi Huda Y | Director | Nov 03 | Open-market sale · S Common Stock | −500 | $971.06 | −$486K | 1,703 |
| Zoghbi Huda Y | Director | Nov 03 | Open-market sale · S Common Stock | −6,939 | $970.42 | −$6.73M | 2,203 |
| Zoghbi Huda Y | Director | Nov 03 | Exercise / conversion · M Common Stock | +7,439 | $380.95 | +$2.83M | 9,142 |
| Fenimore Christopher R. | EVP Finance CFO | Nov 02 | Gift · G Common Stock | −15 | — | — | 21,726 |
| Fenimore Christopher R. | EVP Finance CFO | Nov 02 | Withheld — tax / exercise cost · F Common Stock | −4,243 | $950.50 | −$4.03M | 21,741 |
| Fenimore Christopher R. | EVP Finance CFO | Nov 02 | Exercise / conversion · M Common Stock | +6,000 | $381.92 | +$2.29M | 25,984 |
| Larosa Joseph J | EVP General Counsel and Secret | Nov 02 | Open-market sale · S Common Stock | −527 | $966.11 | −$509K | 38,906 |
| Larosa Joseph J | EVP General Counsel and Secret | Nov 02 | Open-market sale · S Common Stock | −3,939 | $965.41 | −$3.8M | 39,433 |
Loading...